Q-omics provides the consensus-scored NME1 profile across patient tissues and cancer cell-line models. NME1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NME1 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, NME1 RNA expression shows 21,789 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where NME1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NME1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NME1 survival associations across molecular data types. NME1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NME1 RNA expression–survival associations across cancer types. High NME1 expression shows unfavorable associations in KIRC, ACC, MESO, UVM, SKCM and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NME1 RNA expression.
This table summarizes NME1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NME1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NME1 shows higher tumor expression in COAD, HNSC, KIRC, BLCA, KIRP and LUAD. The COAD box plot shows higher NME1 RNA expression in tumor versus normal tissue (log2 FC = +2.306, t-test p < 0.001).
This table shows molecular features associated with NME1 in patient tissues and cancer cell lines. In patient samples, NME1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NME1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
